Your browser doesn't support javascript.
loading
Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).
Huang, Shujie; Wu, Hansheng; Cheng, Chao; Zhou, Ming; Xu, Enwu; Lin, Wanli; Wang, Guangsuo; Tang, Jiming; Ben, Xiaosong; Zhang, Dongkun; Xie, Liang; Zhou, Haiyu; Chen, Gang; Zhuang, Weitao; Tang, Yong; Xu, Fangping; Du, Zesen; Xie, Zefeng; Wang, Feixiang; He, Zhe; Zhang, Hai; Sun, Xuefeng; Li, Zijun; Sun, Taotao; Liu, Jianhua; Yang, Shuhan; Xie, Songxi; Fu, Junhui; Qiao, Guibin.
Afiliação
  • Huang S; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Wu H; Shantou University Medical College, Shantou, China.
  • Cheng C; Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Zhou M; Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Xu E; Department of Thoracic Surgery, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
  • Lin W; Department of Thoracic Surgery, General Hospital of Southern Theater Command, PLA, Guangzhou, China.
  • Wang G; Department of Thoracic Surgery, Gaozhou People's Hospital, Gaozhou, China.
  • Tang J; Department of Thoracic Surgery, Shenzhen Institute of Respiratory Disease, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.
  • Ben X; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhang D; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Xie L; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhou H; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Chen G; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhuang W; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Tang Y; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Xu F; Shantou University Medical College, Shantou, China.
  • Du Z; Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Xie Z; Department of Pathology and Laboratory Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Wang F; Department of Surgical Oncology, Shantou Central Hospital, Shantou, China.
  • He Z; Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Zhang H; Department of Thoracic Surgery, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
  • Sun X; Department of Thoracic Surgery, General Hospital of Southern Theater Command, PLA, Guangzhou, China.
  • Li Z; Department of Thoracic Surgery, Gaozhou People's Hospital, Gaozhou, China.
  • Sun T; Department of Thoracic Surgery, Shenzhen Institute of Respiratory Disease, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.
  • Liu J; Department of General Practice, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Yang S; Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Xie S; WeiLun PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Fu J; Department of Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Qiao G; Chronic Disease Laboratory, School of Medicine, South China University of Technology, Guangzhou, China.
Front Immunol ; 13: 935374, 2022.
Article em En | MEDLINE | ID: mdl-35911702
Purpose: The present study sets out to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a real-world scenario. Materials and Methods: In this multi-center, real-world study (NCT04822103), patients who had unresectable ESCC disease were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every 3 weeks for at least two cycles. Patients with significant relief of cancer-related clinical symptoms and radiological responsive disease were deemed surgical candidates. Feasibility and safety profile of immunochemotherapy plus conversion surgery, radiological and pathological tumor responses, as well as short-term survival outcomes were evaluated. Moreover, data of an independent ESCC cohort receiving induction chemotherapy (iC) were compared. Results: One hundred and fifty-five patients were enrolled in the final analysis. Esophagectomy was offered to 116 patients, yielding a conversion rate of 74.8%. R0 resection rate was 94%. Among the 155 patients, 107 (69.0%) patients experienced at least one treatment-related adverse event (TRAE) and 45 (29.0%) patients reported grade 3 and above TRAEs. Significant differences in responsive disease rate were observed between iC cohort and induction immunochemotherapy (iIC) cohort [objective response rate: iIC: 63.2% vs. iC: 47.7%, p = 0.004; pathological complete response: iIC: 22.4% vs. iC: 6.7%, p = 0.001). Higher anastomosis fistula rate was observed in the iC group (19.2%) compared with the iIC group (4%). Furthermore, Significantly higher event-free survival was observed in those who underwent conversion surgery. Conclusion: Our results supported that conversion surgery following immunochemotherapy is feasible and safe for patients with initially unresectable locally advanced ESCC. Both radiological and pathological response rates were significantly higher in the iIC cohort compared with those in the traditional iC cohort.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article